N/A N=87 Multicenter Clinical Observation PROMOS®
Primary and Secondary Omarthrosis
Primary: Radiological and Clinical Loosening Rates of the Glenoid and Humeral Components — 96.29 Percentage survivorship
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=19 Effects of Exenatide on Hypothalamic Obesity
Hypothalamic Obesity
Primary: BMI Change — -0.77 kg/m^2 — p=.05
Phase 3 N=77 Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?
Glaucoma
Primary: Intraocular Pressure (IOP) — 16.1; 12.8; 11.7; 11.8 mm Hg
Phase 2 N=57 Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
Recurrent Melanoma · Stage IV Skin Melanoma
Primary: Objective Response Rate — 1; 0; 6 patients
Phase 2 N=15 Buprenorphine for Late-Life Treatment Resistant Depression
Depression
Primary: Montgomery Asberg Depression Rating Scale — 9.5 units on a scale
Phase 2 N=15 Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
Chronic Kidney Disease · Cardiovascular Disease
Primary: Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to 12 Weeks — -2.6; 0.8 mg/dl — p=0.03
Phase 3 N=13 Buprenorphine for Treatment Resistant Depression
Depression · Depressive Disorder · Depressive Disorder, Major
Primary: Montgomery Asberg Depression Rating Scale — 33.8; 32.6 units on a scale
Phase 2 N=40 Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
Male Breast Carcinoma · Recurrent Breast Carcinoma · Stage IIIC Breast Cancer AJCC v7
Primary: Confirmed Response Rate (Percentage of Participants With Complete or Partial Response Noted as the Objective Status on Two Consecutive Evaluations at Least 4 Weeks…
Phase 3 N=272 Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
Squamous Cell Non-small Cell Lung Cancer
Primary: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint — 9.23; 6.01 months — p=0.0002
Phase 2 N=44 Randomized Trial of Suicide Gene Therapy and Prostate Cancer
Prostate Cancer
Primary: Freedom From Biochemical/Clinical Failure (FFF) — 20; 21 participants
Phase 4 N=183 Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.
Type 2 Diabetes Mellitus
Primary: Adjusted Mean Change in HbA1c Levels — -0.55; 0.05 percentage of hemoglobin glycosylated — p=<0.0001
Phase 3 N=458 A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (%) Glycosylated Haemoglobin) — -0.54; -0.62; -0.57; -0.59 Percent (%) glycosylated haemoglobin
Phase 3 N=33 A Pilot Study of Oxaloacetate in Subjects With Treated PD
Parkinson's Disease
Primary: Unified Parkinson's Disease Rating Scale (UPDRS) Total Score — 41.1; 42.9; 34.9; 34.4 units on a scale — p=0.50
Phase 2 N=1,310 Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Staphylococcal Infection
Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…
Phase 2 N=42 Randomized Controlled Study of Donepezil in Fragile X Syndrome
Fragile X Syndrome
Primary: Contingency Naming Test (CNT) Performance Score — 37.05; 40.50; 66.94; 61.56 correct responses per minute